Next-generation sequencing for non-colorectal GI tumors

Gastrointestinal stromal tumors (GIST)

Our next-generation sequencing assay for noncolorectal GI cancer assists in diagnosis, including mutations in the most commonly mutated PDGFRA and KIT genes, which are present in 85%-90% of gastrointestinal stromal tumors (GIST), along with NF1, BRAF, and other RAS genes. The test also includes detection of SETD2 and TP53 mutations, which have been shown to take on an aggressive clinical course.

Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.

Key testing

Additional testing

Comprehensive panel boosts GIST diagnosis sensitivity  

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Learn more about how to order these evaluations at your institution.